PVG Escalates Proxy Fight With Detailed Board Critique and Funding Warning Ahead of Sept 24 Vote

summarizeSummary

PVG Asset Management posted a new presentation to its proxy website detailing why Anavex's board should be replaced, adding specific ownership data, a funding shortfall warning for the Alzheimer's trial, and a list of nine departed executives.

check_boxKey Events · Corporate Governance and Compliance · AVXL

• PVG Posts New Board Critique Presentation

  PVG Asset Management posted a new presentation to www.anavexvotepvg.com on September 9, 2026, comparing its six nominees against Anavex's four incumbent directors ahead of the September 24 shareholder vote.

• Incumbent Board Ownership Called Minimal

  PVG alleges the four incumbent board nominees collectively own only 5,000 shares (0.005% of the company), with three of the four owning no shares at all, arguing they have no skin in the game.

• Alzheimer's Trial Funding Shortfall Claimed

  PVG claims Anavex cannot fund its planned Alzheimer's Phase 3 trial, estimated at $150 million, with only $118 million in available cash — a shortfall of approximately $32 million.

• Nine Executive Departures Listed

  PVG lists nine named former executives who departed Anavex in 2026, including the VP of Biostatistics, SVP of Nonclinical Development, and Global Head of Neurology, as evidence of significant brain drain.

auto_awesomeAnalysis · AVXL · Life Sciences

PVG Asset Management posted a new presentation to its proxy website on September 9, 2026, adding materially new ammunition to its campaign to replace Anavex's entire board. The presentation includes side-by-side comparisons of PVG's six nominees against the four incumbent directors, alleging the incumbents collectively own only 5,000 shares (0.005% of the company) and lack CNS drug development expertise. PVG also claims Anavex cannot fund its planned Alzheimer's Phase 3 trial — estimated at $150 million — with only $118 million in available cash, and lists nine named executives who departed in 2026 as evidence of brain drain. The filing comes two weeks before the September 24 shareholder vote and follows a series of escalating DFAN14A filings from PVG, each adding new allegations. The detailed ownership data and funding shortfall analysis represent new material facts not previously disclosed in PVG's earlier proxy materials.